Mitsui Chemicals to Buy JSR for ¥1.84 Trillion in Japan's Largest Chemicals Deal

Combining the two will make the group one of Japan's leading semiconductor materials companies by sales. That is Mitsui's own description in the filing.

Reuters called the deal the largest in Japan's chemicals sector. It exceeds Showa Denki's $4.55 billion acquisition of Hitachi Chemical in 2020.

Mitsui aims for about ¥40 billion in additional annual profit by fiscal 2035. The figure is a company target from growth and cost synergies, not a result.

Mitsui takes every vote; DBJ takes preferred shares

The sellers of record are JIC PEFJ1 Limited Partnership and JIC PEF1 Limited Partnership. The funds, managed by JIC Capital, held 89.72% and 6.75% of JSR.

They hold the JSR common shares Mitsui and DBJ will acquire for cash.

Mitsui and DBJ will also buy the Class A and Class B preferred shares. Those shares are held by Mizuho Bank and DBJ today.

Both preferred classes are set to convert into common shares after completion. DBJ's common shares will then convert into non-voting preferred shares.

The result is simple: Mitsui will hold 100% of the voting rights in JSR. DBJ will hold an economic stake without a vote.

Four JSR affiliates will also become Mitsui subsidiaries. They include Inpria, a United States maker of metal-oxide resists for EUV lithography.

EUV, or extreme ultraviolet, is the newest chip-printing technology. Inpria develops resists, the coatings that carry circuit patterns, for it.

Financing a deal larger than the buyer

Mitsui plans a ¥1.64 trillion bridge loan from its principal banks. DBJ's ¥200 billion investment completes the planned funding.

A bridge loan is short-term borrowing used until permanent financing is arranged. Mitsui intends to refinance it with bank loans, bonds and equity.

The company filed a shelf registration for up to ¥150 billion of common shares. The proceeds would partly repay the bridge loan.

A shelf registration lets a company sell shares later under one filing. The registration takes effect on November 17, 2026, and runs for two years.

Mitsui also plans ¥300 billion of mezzanine financing. Mezzanine financing sits between ordinary debt and equity in risk and return.

It targets ¥300 billion of rating-agency equity credit within a year of completion. Half the mezzanine amount is assumed to count as equity for that purpose.

Mitsui expects net debt to exceed four times EBITDA after completion, temporarily. EBITDA is earnings before interest, taxes, depreciation and amortization.

It aims to keep an issuer credit rating in the A category. Restoring financial soundness quickly is the stated reason for the refinancing plan.

Mitsui's market value stood at ¥664.6 billion at Friday's close, LSEG data cited by Reuters showed. That is well below the agreed price.

Mitsui shares closed at ¥1,586 on Monday, down 8.5% on the day, Reuters reported. Friday's close was ¥1,733, so the settled fall was 8.48% on market data.

Market participants question the rationale and the heavy debt load, Reuters said. The fall extended last week's slide after reports named Mitsui the buyer.

Buying JSR is 'not simply about strengthening our semiconductor materials business,' chief executive Satoshi Ichimura told a press conference. It is 'a strategic deal to accelerate the transformation of our portfolio,' Reuters reported him saying.

Japan Investment Corp bought JSR for ¥900 billion in 2024. It then planned to use JSR to drive consolidation in semiconductor materials.

The fund is instead selling into an AI-driven lift in chip-company valuations, Reuters reported. JIC Capital chief executive Shogo Ikeuchi said seven or eight potential buyers were considered since spring.

JSR will keep treating its life sciences businesses as non-core and explore all options, the filing said. Reuters reported Mitsui plans to sell that unit and other non-core businesses.

Approvals stand between signing and closing

Completion needs competition and foreign-investment procedures in Japan and overseas. Mitsui aims to complete in the second half of the fiscal year ending March 2028.

That timing may change with the approval procedures, the company said. The deal's effect on results for the year ending March 2027 will be minor.

What remains unknown

What remains unknown starts with the final price. Closing adjustments will determine the exact consideration Mitsui and DBJ pay.

The approval timetable is also unknown. No exact closing date has been set inside the targeted second half.

The permanent financing mix is not final either. The rating agencies' treatment of the mezzanine financing is an assumption, not a decision.

How far the share slide extends is also unknown. Monday's close is one session's verdict, not a settled valuation of the deal.

What happens to JSR's life sciences businesses is also undecided. So is the pace of the profit gains Mitsui targets for 2035.

The approvals come first

What to watch: the competition and foreign-investment approvals in Japan and overseas. They gate the targeted completion in the second half of the year ending March 2028.

The November 17 shelf effectiveness is the first financing date. Any share issuance under it will show how the refinancing is taking shape.

Mitsui's settled closes after Monday will show whether the 8.5% verdict holds. Full integration plans after closing will test the 2035 profit target.

XenoSpectrum

XenoSpectrum - Mitsui Chemicals to Buy JSR for ¥1.84 Trillion, Nov. 9, 2026